BPI Update Digital: China Pharma 2026 Regulatory Trends & Emerging Developments

China’s pharmaceutical regulatory landscape continues to evolve, with major regulatory reforms, changing NMPA requirements, and increasing alignment with international standards influencing drug development, registration, and lifecycle strategies.

On September 8, 2026, as part of the BPI Update Digital series, Stefanie Fasshauer, Life Sciences Business Development Director at Cisema, presented “China Pharma 2026: Regulatory Trends and Emerging Developments.” The session examined recent regulatory developments and their practical implications for pharmaceutical companies operating in China.

Key Takeaways from the Webinar

The session covered key developments across China’s pharmaceutical regulatory landscape, including:

What’s Changing in China’s Regulatory Framework?

• 2026 drug regulatory reforms
• NMPA priorities and regulatory data protection
• ICH implementation and the new GCP framework

Advances in Drug Development and Registration

• Electronic Common Technical Document (eCTD) implementation
• Acceptance and use of overseas clinical data
• Evolving clinical development approaches
• Combination products

The Evolving Quality and Compliance Landscape

• Electronic Batch Records (EBRs)
• Process validation
• Post-approval lifecycle management
• Current inspection trends

Emerging Trends: From AI to Generics and Biosimilars

• Artificial intelligence and digital regulation
• Regulatory science
• Generics and biosimilars

The discussion highlighted how these developments are shaping regulatory planning, clinical and CMC development, lifecycle management, and market access strategies for pharmaceutical companies in China.

About BPI – German Pharmaceutical Industry Association

For more than 70 years, the German Pharmaceutical Industry Association (BPI) has represented the pharmaceutical industry, with around 260 member companies ranging from global corporations to SMEs and start-ups. Through advocacy, regulatory expertise, industry insights, and specialist working groups, BPI supports its members and contributes to the pharmaceutical policy and regulatory environment in Germany and Europe.

Further Information

To learn more about Cisema's support for pharmaceutical companies operating in China, including regulatory strategy, registration, compliance, and lifecycle management, explore Cisema's Pharma Consulting services.